FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4290791780> ?p ?o ?g. }

• W4290791780 abstract "Abstract COVID-19 strongly influences our daily lives, and there is urgent need for a therapy treating early infections to prevent progression.CARVIN was a randomized, parallel, double-blind, placebo-controlled study. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0·02% or 0·1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. Investigators assessed patients’ status throughout the trial including safety follow-ups (days 16 and 60). Symptoms were documented in patient diaries.Initial viral loads were log 10 6·85 ± 1·31 (mean ± SD) copies/mL (ORF 1a/b gene). After treatment, virus load was reduced in all groups (p<0·0001), but was greater in the 0·1% group compared to placebo (p=0·007). In a subset of patients (initial Ct<25) viral load was strongly reduced on day 4 in the 0·1% group compared to placebo (p=0·005). Negative PCR results appeared earlier and more frequently in the azelastine treated groups: being 18·52% and 21·43% in the 0·1% and 0·02% groups, respectively, compared to 0% for placebo on day 8. Comparable numbers of adverse events occurred in all treatment groups with no safety concerns.The shown effects of azelastine nasal spray may thus be suggestive of azelastine’s potential as an antiviral treatment. Trial Registration :The study was registered in the German Clinical Trial Register (DRKS-ID: DRKS00024520; Date of Registration in DRKS: 12/02/2021).EudraCT number: 2020-005544-34" @default.
• W4290791780 created "2022-08-09" @default.
• W4290791780 creator A5000276878 @default.
• W4290791780 creator A5001906488 @default.
• W4290791780 creator A5007665606 @default.
• W4290791780 creator A5014375585 @default.
• W4290791780 creator A5017742394 @default.
• W4290791780 creator A5018126455 @default.
• W4290791780 creator A5019675594 @default.
• W4290791780 creator A5019998508 @default.
• W4290791780 creator A5022527420 @default.
• W4290791780 creator A5029963510 @default.
• W4290791780 creator A5029994251 @default.
• W4290791780 creator A5030080446 @default.
• W4290791780 creator A5043137167 @default.
• W4290791780 creator A5047428513 @default.
• W4290791780 creator A5053719823 @default.
• W4290791780 creator A5063277586 @default.
• W4290791780 creator A5063655637 @default.
• W4290791780 creator A5065176023 @default.
• W4290791780 creator A5066205556 @default.
• W4290791780 creator A5072271077 @default.
• W4290791780 creator A5075833715 @default.
• W4290791780 creator A5077702058 @default.
• W4290791780 creator A5081043920 @default.
• W4290791780 creator A5082575667 @default.
• W4290791780 creator A5084140575 @default.
• W4290791780 creator A5086282112 @default.
• W4290791780 creator A5086835391 @default.
• W4290791780 date "2022-08-09" @default.
• W4290791780 modified "2023-10-18" @default.
• W4290791780 title "COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN) Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients – results from a randomized, double-blind, placebo-controlled phase II clinical trial." @default.
• W4290791780 cites W1977306693 @default.
• W4290791780 cites W1990845575 @default.
• W4290791780 cites W2008787901 @default.
• W4290791780 cites W2933138968 @default.
• W4290791780 cites W3013359483 @default.
• W4290791780 cites W3013893137 @default.
• W4290791780 cites W3034858522 @default.
• W4290791780 cites W3047719754 @default.
• W4290791780 cites W3094560806 @default.
• W4290791780 cites W3106854997 @default.
• W4290791780 cites W3109172892 @default.
• W4290791780 cites W3125038587 @default.
• W4290791780 cites W3125712166 @default.
• W4290791780 cites W3150351745 @default.
• W4290791780 cites W3165359464 @default.
• W4290791780 cites W3204426344 @default.
• W4290791780 cites W4220904663 @default.
• W4290791780 cites W4283735086 @default.
• W4290791780 doi "https://doi.org/10.21203/rs.3.rs-1893502/v1" @default.
• W4290791780 hasPublicationYear "2022" @default.
• W4290791780 type Work @default.
• W4290791780 citedByCount "0" @default.
• W4290791780 crossrefType "posted-content" @default.
• W4290791780 hasAuthorship W4290791780A5000276878 @default.
• W4290791780 hasAuthorship W4290791780A5001906488 @default.
• W4290791780 hasAuthorship W4290791780A5007665606 @default.
• W4290791780 hasAuthorship W4290791780A5014375585 @default.
• W4290791780 hasAuthorship W4290791780A5017742394 @default.
• W4290791780 hasAuthorship W4290791780A5018126455 @default.
• W4290791780 hasAuthorship W4290791780A5019675594 @default.
• W4290791780 hasAuthorship W4290791780A5019998508 @default.
• W4290791780 hasAuthorship W4290791780A5022527420 @default.
• W4290791780 hasAuthorship W4290791780A5029963510 @default.
• W4290791780 hasAuthorship W4290791780A5029994251 @default.
• W4290791780 hasAuthorship W4290791780A5030080446 @default.
• W4290791780 hasAuthorship W4290791780A5043137167 @default.
• W4290791780 hasAuthorship W4290791780A5047428513 @default.
• W4290791780 hasAuthorship W4290791780A5053719823 @default.
• W4290791780 hasAuthorship W4290791780A5063277586 @default.
• W4290791780 hasAuthorship W4290791780A5063655637 @default.
• W4290791780 hasAuthorship W4290791780A5065176023 @default.
• W4290791780 hasAuthorship W4290791780A5066205556 @default.
• W4290791780 hasAuthorship W4290791780A5072271077 @default.
• W4290791780 hasAuthorship W4290791780A5075833715 @default.
• W4290791780 hasAuthorship W4290791780A5077702058 @default.
• W4290791780 hasAuthorship W4290791780A5081043920 @default.
• W4290791780 hasAuthorship W4290791780A5082575667 @default.
• W4290791780 hasAuthorship W4290791780A5084140575 @default.
• W4290791780 hasAuthorship W4290791780A5086282112 @default.
• W4290791780 hasAuthorship W4290791780A5086835391 @default.
• W4290791780 hasBestOaLocation W42907917801 @default.
• W4290791780 hasConcept C126322002 @default.
• W4290791780 hasConcept C141071460 @default.
• W4290791780 hasConcept C142462285 @default.
• W4290791780 hasConcept C142724271 @default.
• W4290791780 hasConcept C168563851 @default.
• W4290791780 hasConcept C197934379 @default.
• W4290791780 hasConcept C203014093 @default.
• W4290791780 hasConcept C204787440 @default.
• W4290791780 hasConcept C2522874641 @default.
• W4290791780 hasConcept C27081682 @default.
• W4290791780 hasConcept C2777844070 @default.
• W4290791780 hasConcept C2778311950 @default.
• W4290791780 hasConcept C2779134260 @default.
• W4290791780 hasConcept C2780113039 @default.
• W4290791780 hasConcept C2780973058 @default.
• W4290791780 hasConcept C3008058167 @default.
• W4290791780 hasConcept C42219234 @default.

• next